Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial
Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarthritis in the coming months.
The series D funding was led by New Enterprise Associates (NEA) with assistance from new and existing investors including ArrowMark Partners, Quan Capital.
Pfizer and Arvinas in a USD 830 million deal to target multiple therapeutic areas
Arvinas, a private biopharmaceutical company focused on developing first-in-class small mol...
